Baird MJ, Carson RT, Ervin CM, Chang L, Spiegel B, Norton NJ, Lackner J, Lasch K, Fehnel SE. Qualitative assessment of symptom experience in patients with irritable bowel syndrome for the development of patient reported outcome instruments. Poster presented at the 2013 Digestive Disease Week; May 2013.
Lenderking WR, Coon C, Fehnel SE, Burke L. The utility of mixed-method approaches to evaluate the content validity of patient-reported outcome measures. Presented at the International Society for Pharmacoeconomics and Outcomes Research; May 1, 2013.
Fehnel SE. Choice of recall period in patient-reported outcome measurement. Presented at the 4th Annual Patient-Reported Outcome Consortium Workshop; April 1, 2013.
Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A. FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):441-6.
Bell C, McLeod LD, Nelson LM, Fehnel SE, Zografos LJ, Bowers B. Development and psychometric evaluation of a new patient-reported outcome instrument measuring the functional impact of insomnia. Qual Life Res. 2011 Nov 1;20(9):1457-68.
Williams VS, Nelson LM, Gilligan TM, Fehnel SE, Baird MJ, Carson RT. The relationship between changes in PRO measures of IBS-C symptoms and the IBS-QOL: results from two phase 3 trials of linaclotide. Poster presented at the 18th Annual Conference of the International Society for Quality of Life Research; October 1, 2011.
Nelson LM, Williams VS, Gilligan TN, Fehnel SE, Baird MJ, Carson RT. Examining the relationship between changes in pro measures of chronic constipation symptoms and the pac-qol: results from two phase 3 trials of linaclotide. Poster presented at the 18th Annual Conference of the International Society for Quality of Life Research; October 1, 2011.
Mangel AW, Fehnel SE. End points in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2011 Jun 1;5(3):293-5.
Mordin M, Clark M, DeMuro C, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Pro label claims: an analysis based on a review of pros among new molecular entities and biologic license applications 2006-2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
DeMuro C, Mordin M, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: uS FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 1;11(2):163-9.
Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research. 2011 Feb 1;4(1):9-12.
Deal LS, Williams VSL, Fehnel SE. Development of an electronic daily uterine fibroid symptom diary. Patient. 2011 Jan 1;4(1):31-44.